发明名称 ISOSERINE DERIVATIVES APPLIED AS BLOOD COAGULATION FACTOR IXA INHIBITORS
摘要 FIELD: medicine, pharmaceutics. ^ SUBSTANCE: present invention refers to compounds of formula I ^ and/or to all isomer forms of a compound of formula I and/or to mixtures of these forms in any proportions, and/or to physiologically acceptable salts of the compound of formula I, wherein R1 represents 1) -(C6-C14)-aryl-Z, wherein Z represents aminomethylene, 2) Het-Z, wherein Z represents amino group, and wherein Het is unsubstituted or additionally monosubstituted by group T, R2 represents 1) -(C0)-alkylene-(C6-C14)aryl, wherein aryl is unsubstituted or mono- or disubstituted by group T or 2) -(C0)-alkylene-Het, wherein Het is unsubstituted or monosubstituted by group T, R3 represents 1) -(C0)-alkylene-(C6-C14)-aryl, wherein aryl is unsubstituted or mono- or disubstituted by group T, 2) -O-(C6-C14)-alkylene(C6-C14)-aryl, wherein aryl is unsubstituted or monosubstituted by group T, 3) -(C0)-alkylene-Het, wherein Het is unsubstituted or mono-, di- or trisubstituted by group T, 4) -(C0)-alkylene-(C6-C14)-aryl-Q-(C6-C14)-aryl, wherein both aryl radicals are unsubstituted, 5) -(C0)-alkylene-(C6-C14)-aryl-Q)-Het, wherein aryl and Het in each case are independently unsubstituted or disubstituted by group T, 6) -(C0)-alkylene-Het-Q-Het, wherein both radicals Het are unsubstituted, Q represents a covalent bond, -(C1-C4)-alkylene, -N((C1-C4)-alkyl)- or -O-, T represents 1) halogen, 2) -(C1-C6)-alkyl, wherein alkyl is unsubstituted disubstituted by group -(C1-C3)-fluoralkyl or -N-C(O)-(C1-C4)-alkyl, 3) -(C1-C3)-fluoralkyl, 4) -(C3-C8)-cycloalkyl, 5) -O-(C1-C4)-alkyl, 6) -O-(C1-C3)-fluoralkyl, 7) -N(R10)(R11), wherein R(10) and R(11) independently represent hydrogen atom or -(C1-C6)-alkyl, 8) -C(O)-NH-R10, 9) -SO2-(C1-C4)-alkyl, 10) -SO2-(C1-C3)-fluoralkyl, R4 and R5 are identical and represent hydrogen atom, and R6 represent hydrogen atom with said Het being 5-10-member ring system consisting of 1 or 2 coupled ring systems, and wherein one or two identical or different heteroatoms are selected from oxygen, nitrogen and sulphur. Also, the invention refers to the use of the compound of formula I for preparing a drug. ^ EFFECT: there are prepared new compounds exhibiting antithrombotic activity, which particularly inhibit blood coagulation factor lXa. ^ 6 cl, 2 tbl, 9 ex
申请公布号 RU2446157(C2) 申请公布日期 2012.03.27
申请号 RU20090113602 申请日期 2007.08.31
申请人 SANOFI-AVENTIS 发明人 SHTAJNKHAGEN KHENNING;FOLL'MANN MARKUS;GERLITTSER JOKHEN;SHROJDER KHERMAN
分类号 A61K31/166;A61K31/341;A61K31/343;A61K31/381;A61K31/404;A61K31/4184;A61K31/428;A61K31/47;A61K31/505;A61P7/02;C07C237/22;C07D207/34;C07D209/42;C07D213/56;C07D215/48;C07D217/22;C07D235/24;C07D239/28;C07D239/95;C07D241/44;C07D277/82;C07D307/54;C07D307/85;C07D401/12;C07D403/12;C07D405/12 主分类号 A61K31/166
代理机构 代理人
主权项
地址